Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.20%
#2 aelf aelf +23.74%
#3 Bitway Bitway +16.31%
#4 Decred Decred +11.24%
#5 TRIA TRIA +8.74%
#6 Wibx Wibx +8.11%
#7 Pons Pons +7.97%
#8 DexNet DexNet +7.55%
#9 Status Status +7.12%
#10 AtomOne AtomOne +7.07%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
設定
言語
日本
通貨
USD
テーマ
Aelis Farma S.A. Aelis Farma S.A.

Aelis Farma S.A.

AELIS
株式のランク #30387
Aelis Farma S.A., a French biotechnology company founded in 2013 and... Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
株価
$1.25
最終同期: 2026-08-18
時価総額
$17.05M
変化（1日）
-1.50%
変化（1年）
-22.24%
国
FR
取引 Aelis Farma S.A. (AELIS)

カテゴリー

Healthcare
Aelis Farma S.A.（AELIS）の収益
Aug 2026 時点の収益 TTM: 0
Aelis Farma S.A. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Aelis Farma S.A. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE